Literature DB >> 18669641

The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.

Kanchan Anand1, Irantzu Pallares, Zuzana Valnickova, Trine Christensen, Josep Vendrell, K Ulrich Wendt, Herman A Schreuder, Jan J Enghild, Francesc X Avilés.   

Abstract

Mature thrombin-activable fibrinolysis inhibitor (TAFIa) is a highly unstable metallocarboxypeptidase that stabilizes blood clots by clipping C-terminal lysine residues from partially degraded fibrin. In accordance with its in vitro antifibrinolytic activity, animal studies have reported that inhibition of mature TAFI aids in the prevention of thrombosis. The level of TAFI activity is stringently regulated through (i) controlled proteolytic truncation of the zymogen (TAFI), generating the mature enzyme, TAFIa, and (ii) the short half-life of TAFIa. TAFI itself exhibits an intrinsic enzymatic activity, which is likely required to provide a baseline level of antifibrinolytic activity. The novel crystal structure presented here reveals that the active site of TAFI is accessible, providing the structural explanation for the its intrinsic activity. It also supports the notion that an "instability region" exists, in agreement with site-directed mutagenesis studies. Sulfate ions, bound to this region, point toward a potential heparin-binding site and could explain how heparin stabilizes TAFIa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669641      PMCID: PMC2662027          DOI: 10.1074/jbc.M804003200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor.

Authors:  M B Boffa; R Bell; W K Stevens; M E Nesheim
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

2.  Likelihood-enhanced fast rotation functions.

Authors:  Laurent C Storoni; Airlie J McCoy; Randy J Read
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-02-25

3.  Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.

Authors:  E Ceresa; M De Maeyer; A Jonckheer; M Peeters; Y Engelborghs; P J Declerck; A Gils
Journal:  J Thromb Haemost       Date:  2007-07-31       Impact factor: 5.824

4.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

5.  Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen.

Authors:  W Wang; D F Hendriks; S S Scharpé
Journal:  J Biol Chem       Date:  1994-06-03       Impact factor: 5.157

6.  The three-dimensional structure of human procarboxypeptidase A2. Deciphering the basis of the inhibition, activation and intrinsic activity of the zymogen.

Authors:  I García-Sáez; D Reverter; J Vendrell; F X Avilés; M Coll
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

7.  Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation.

Authors:  Zuzana Valnickova; Trine Christensen; Peter Skottrup; Ida B Thøgersen; Peter Højrup; Jan J Enghild
Journal:  Biochemistry       Date:  2006-02-07       Impact factor: 3.162

Review 8.  A role for procarboxypepidase U (TAFI) in thrombosis.

Authors:  Johan L Willemse; Dirk F Hendriks
Journal:  Front Biosci       Date:  2007-01-01

Review 9.  Thrombin and fibrinolysis.

Authors:  Michael Nesheim
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

10.  Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Authors:  L Bajzar; R Manuel; M E Nesheim
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

View more
  5 in total

1.  Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.

Authors:  Zuzana Valnickova; Laura Sanglas; Joan L Arolas; Steen V Petersen; Christine Schar; Daniel Otzen; Francesc X Aviles; F Xavier Gomis-Rüth; Jan J Enghild
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

2.  The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.

Authors:  Chengliang Wu; Paul Y Kim; Reg Manuel; Marian Seto; Marc Whitlow; Mariko Nagashima; John Morser; Ann Gils; Paul Declerck; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

Review 3.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

4.  Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).

Authors:  Herman Schreuder; Alexander Liesum; Petra Lönze; Heike Stump; Holger Hoffmann; Matthias Schiell; Michael Kurz; Luigi Toti; Armin Bauer; Christopher Kallus; Christine Klemke-Jahn; Jörg Czech; Dan Kramer; Heike Enke; Timo H J Niedermeyer; Vincent Morrison; Vasant Kumar; Mark Brönstrup
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

5.  Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Authors:  Zuzana Valnickova; Morten Thaysen-Andersen; Peter Højrup; Trine Christensen; Kristian W Sanggaard; Torsten Kristensen; Jan J Enghild
Journal:  BMC Biochem       Date:  2009-05-05       Impact factor: 4.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.